Exchange Traded Concepts’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.44M Buy
169,950
+23,716
+16% +$1.09M 0.03% 455
2026
Q2
$7.01M Sell
146,234
-37,600
-20% -$1.62M 0.03% 425
2026
Q1
$6.76M Buy
183,834
+12,166
+7% +$576K 0.05% 354
2025
Q4
$8.73M Buy
171,668
+64,199
+60% +$3.28M 0.07% 293
2025
Q3
$5.96M Buy
107,469
+19,516
+22% +$1.14M 0.05% 350
2025
Q2
$6.07M Buy
87,953
+20,084
+30% +$1.37M 0.07% 278
2025
Q1
$4.71M Sell
67,869
-2,636
-4% -$218K 0.08% 212
2024
Q4
$6.06M Buy
70,505
+6,543
+10% +$708K 0.12% 185
2024
Q3
$7.62M Buy
63,962
+18,370
+40% +$2.45M 0.18% 138
2024
Q2
$6.51M Buy
+45,592
New +$6.04M 0.16% 151

Other funds holding NVO

Exchange Traded Concepts's NVO Position: Q3 2026 in Review

Exchange Traded Concepts increased its Novo Nordisk (NVO) stake by 16% in Q3 2026, buying an estimated $1.09M and bringing the position to 169,950 shares worth $6.44M. The position accounts for 0.03% of the portfolio, ranked #455.

Exchange Traded Concepts first reported a position in NVO in Q2 2024 and has held it in 10 quarters since. The position peaked at $8.73M in Q4 2025. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Exchange Traded Concepts held 169,950 shares of Novo Nordisk worth $6.44M as of Q3 2026.
  • Exchange Traded Concepts bought 23,716 Novo Nordisk shares in Q3 2026, an estimated $1.09M.
  • Novo Nordisk made up 0.03% of Exchange Traded Concepts's portfolio in Q3 2026, its #455 holding.
  • Exchange Traded Concepts first reported a position in Novo Nordisk in Q2 2024 and has held it in 10 quarters since.
  • Exchange Traded Concepts's Novo Nordisk position peaked at $8.73M in Q4 2025.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Exchange Traded Concepts's 13F filing for Q3 2026, filed 28 Oct 2026.